Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEV2A + PEV2B
- Development stage
- Discontinued
- Lead developer
- Pevion Biotech
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PEV2A + PEV2B is a therapeutic vaccine candidate developed by Pevion Biotech AG for the treatment of chronic hepatitis C virus (HCV) infection. The vaccine utilizes a combination of Pevion's proprietary PeviPRO and PeviTER platforms to induce a comprehensive cellular immune response. PEV2A is a virosome-formulated component designed to stimulate a CD4+ helper T-cell response, while PEV2B consists of two virosome-formulated components targeting a CD8+ cytotoxic T-lymphocyte (CTL) response. By delivering synthetic peptide antigens derived from the hepatitis C virus via virosomes, the vaccine aims to overcome the immune tolerance often seen in chronic HCV infection. Clinical development reached Phase I trials but the program has since been discontinued.
- Other names
- PEV2A + PEV2BPevion HCV vaccine
02
Targets
SA (Sialic acid)MHC I (MHC class I})γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on PEV2A + PEV2B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEV2A + PEV2B.